Medivation’s Prostate Cancer Drug Approved by U.S. FDA

Medivation Inc., a biotechnology company whose shares have jumped sixfold in the past 12 months, won approval from U.S. regulators for a late-stage prostate cancer treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.